Literature DB >> 17215121

Expression of p53 isoforms in squamous cell carcinoma of the head and neck.

Linda Boldrup1, Jean-Christophe Bourdon, Philip J Coates, Björn Sjöström, Karin Nylander.   

Abstract

Recent data indicate that, similar to p63 and p73, several different p53 isoforms can be produced in humans through alternative initiation of translation, usage of an internal promoter and alternative splicing. These isoforms are reported to have varying functions and expressions. In squamous cell carcinoma of the head and neck (SCCHN), disruption of the p53 pathway is one of the most common genetic alterations. However, to our knowledge, no studies regarding the expression of different p53 isoforms in SCCHN have so far been performed. We screened for the expression of different p53 isoforms in SCCHN and clinically normal oral epithelia using nested RT-PCR. p53 mRNA was expressed in all tumours, all matched clinically normal tissue adjacent to the tumour and in buccal mucosa from healthy volunteers. Of the novel isoforms, p53beta was detected in the majority of samples analysed, and all of the recently described isoforms were also detected in at least some tumour and normal epithelium samples, with the exception of Deltap53 isoforms. We conclude that p53 variant mRNAs are expressed in both normal oral stratified epithelium and SCCHN. Improvements in methodologies and reagents to detect and quantify p53 isoform expression in clinical material will be required to correlate p53 status with clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215121      PMCID: PMC3523263          DOI: 10.1016/j.ejca.2006.10.019

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  25 in total

1.  Alternatively spliced p53 RNA in transformed and normal cells of different tissue types.

Authors:  K A Han; M F Kulesz-Martin
Journal:  Nucleic Acids Res       Date:  1992-04-25       Impact factor: 16.971

2.  Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.

Authors:  B Vojtesek; H Dolezalova; L Lauerova; M Svitakova; P Havlis; J Kovarik; C A Midgley; D P Lane
Journal:  Oncogene       Date:  1995-01-19       Impact factor: 9.867

3.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.

Authors:  A Yang; M Kaghad; Y Wang; E Gillett; M D Fleming; V Dötsch; N C Andrews; D Caput; F McKeon
Journal:  Mol Cell       Date:  1998-09       Impact factor: 17.970

Review 4.  The p53 pathway.

Authors:  C Prives; P A Hall
Journal:  J Pathol       Date:  1999-01       Impact factor: 7.996

5.  Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers.

Authors:  M Kaghad; H Bonnet; A Yang; L Creancier; J C Biscan; A Valent; A Minty; P Chalon; J M Lelias; X Dumont; P Ferrara; F McKeon; D Caput
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

6.  Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line.

Authors:  V T Chow; H H Quek; E P Tock
Journal:  Cancer Lett       Date:  1993-09-30       Impact factor: 8.679

7.  Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions.

Authors:  C W Stephen; P Helminen; D P Lane
Journal:  J Mol Biol       Date:  1995-04-21       Impact factor: 5.469

8.  The human tumour suppressor gene p53 is alternatively spliced in normal cells.

Authors:  J M Flaman; F Waridel; A Estreicher; A Vannier; J M Limacher; D Gilbert; R Iggo; T Frebourg
Journal:  Oncogene       Date:  1996-02-15       Impact factor: 9.867

9.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53.

Authors:  M Osada; M Ohba; C Kawahara; C Ishioka; R Kanamaru; I Katoh; Y Ikawa; Y Nimura; A Nakagawara; M Obinata; S Ikawa
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

10.  Two new p73 splice variants, gamma and delta, with different transcriptional activity.

Authors:  V De Laurenzi; A Costanzo; D Barcaroli; A Terrinoni; M Falco; M Annicchiarico-Petruzzelli; M Levrero; G Melino
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

View more
  37 in total

1.  Splicing of mouse p53 pre-mRNA does not always follow the "first come, first served" principle and may be influenced by cisplatin treatment and serum starvation.

Authors:  Min Yang; Jack Wu; Si-Hung Wu; An-Ding Bi; D Joshua Liao
Journal:  Mol Biol Rep       Date:  2012-06-28       Impact factor: 2.316

2.  p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage.

Authors:  M Aoubala; F Murray-Zmijewski; M P Khoury; K Fernandes; S Perrier; H Bernard; A-C Prats; D P Lane; J-C Bourdon
Journal:  Cell Death Differ       Date:  2010-08-06       Impact factor: 15.828

3.  Irradiation with heavy-ion particles changes the cellular distribution of human histone acetyltransferase HAT1.

Authors:  Emily A Lebel; Petra Boukamp; Stefan T Tafrov
Journal:  Mol Cell Biochem       Date:  2010-02-11       Impact factor: 3.396

4.  p53 isoform profiling in glioblastoma and injured brain.

Authors:  R Takahashi; C Giannini; J N Sarkaria; M Schroeder; J Rogers; D Mastroeni; H Scrable
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 9.867

5.  Double lethal effects of fusion gene of wild-type p53 and JunB on hepatocellular carcinoma cells.

Authors:  Cheng Guo; Qingguang Liu; Lei Zhang; Xue Yang; Tao Song; Yingmin Yao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-10

6.  Expression of p53β and Δ133p53 isoforms in different gastric tissues.

Authors:  Wansheng Ji; Na Zhang; Hongmei Zhang; Jingrong Ma; Hua Zhong; Jianxin Jiao; Zhixing Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2.

Authors:  I Roth; H Campbell; C Rubio; C Vennin; M Wilson; A Wiles; G Williams; A Woolley; P Timpson; M V Berridge; N Fleming; M Baird; A W Braithwaite
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

8.  Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer.

Authors:  Mirko Marabese; Sergio Marchini; Eleonora Marrazzo; Pietro Mariani; Dario Cattaneo; Roldano Fossati; Anna Compagnoni; Mauro Signorelli; Ute M Moll; A Maria Codegoni; Massimo Broggini
Journal:  Eur J Cancer       Date:  2007-11-26       Impact factor: 9.162

9.  Retinoblastoma gene abnormalities in early laryngeal cancer.

Authors:  Mark Rafferty; Carol Walker; David Husband; Timothy Helliwell; John Fenton; Andrew Jones
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-01-03       Impact factor: 2.503

10.  p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish.

Authors:  Jun Chen; Sok Meng Ng; Changqing Chang; Zhenhai Zhang; Jean-Christophe Bourdon; David P Lane; Jinrong Peng
Journal:  Genes Dev       Date:  2009-02-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.